PATENT CLAIM ANALYSIS

Application Number: 15781997
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["546", "153000"]

Abstract:
Quinoline compounds and salts, hydrates or solvates serving as a selective uric acid reabsorption inhibitor, can be used in the treatment of hyperuricemia and gout by promoting uric acid to excrete from the body and reducing serum uric acid. Such compounds have the effect of reducing the uric acid in the animal body and human body.

Claim (Index 8):
The method for preparation of compounds according to  claim 1 , that is characterized by including the procedure carried out by the following route, or, including the procedure carried out by the following route,

Metadata:
- Claim Count in Document: 4.0
- Percentile: 94.0
- Lexical Diversity: 1.53846
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15357613', '14679866', '14099276', '13093729', '12043456']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7916777589515068
- 35 USC 102 Novelty (BERT): 0.5343785742614657
- Combined Prediction Score: 0.7659478404825028
- Mean Citation Score: 335.818128
- Max Citation Score: 339.1581700000001
- Similarity Product: 178.39483998065182

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test